0.52 -0.02 (-3.70%)

83.54% Fall from 52W High

34,792 XNAS Volume

XNAS 28 Mar, 2025 2:27 PM (EDT)

Board Meeting
The board meeting for Entero Therapeutics Inc. is scheduled for today, for the purpose of First Wave BioPharma Inc Annual Report for 2024 See details


Insider Trading disclosures for Entero Therapeutics Inc.

The latest disclosure was made by Sarah M. Romano in Entero Therapeutics Inc. where a trade of 727 Common Stock done at an average price of $0.6 was reported to US exchanges on Jan. 6, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Sarah M. Romano Chief Financial Officer Sale of securities on an exchange or to another person at price $ 0.64 per share. 06 Jan 2025 727 17,287 (0%) 0% 0.6 465 Common Stock
Sarah M. Romano Chief Financial Officer Sale of securities on an exchange or to another person at price $ 0.45 per share. 09 Oct 2024 476 18,014 (0%) 0% 0.4 212 Common Stock
James Sapirstein Director, Chairman and CEO 02 Jul 2024 1,289 35,816 (0%) 0% 1.1 1,379 Common Stock
Sarah M. Romano Chief Financial Officer Sale of securities on an exchange or to another person at price $ 1.07 per share. 02 Jul 2024 621 18,490 (0%) 0% 1.1 664 Common Stock
Chaitan S. Khosla Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jun 2024 24,889 24,889 (0%) 0% 0 Common Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures